Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06225973 · ClinicalTrials.gov registry record · Phase 2

A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease

A Phase 2 study of Dry Eye Disease, sponsored by Telios Pharma.

Active
Registry status
Phase 2
Development phase
880
Enrollment target
18
Study locations

NCT06225973 is a Phase 2 study of Dry Eye Disease that is active but no longer recruiting, run by Telios Pharma. The registered enrollment target is 880 participants, above the 228-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (286% higher). The trial reports 18 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06225973, a Phase 2 study of Dry Eye Disease, is active but no longer recruiting, sponsored by Telios Pharma.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
880 participants
Enrollment target
18
Study locations

Study Summary

In this prospective, phase 2b, multicenter, randomized, double-masked, vehicle-controlled, parallel-arm study, approximately 880 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive either TL-925 or vehicle as topical ophthalmic eye drops administered bilaterally BID. The study will comprise two phases: a two-week screening phase/run-in and a six-week double-masked treatment phase.

Conditions Studied

Dry Eye Disease

Interventions

  • OTHER Placebo
  • DRUG TL-925

Study Locations (18)

Massachusetts

  • Andover Eye Associates - Andover - Andover
  • Andover Eye Associates - Raynham - Raynham
  • NEERA - Westborough - Westborough
  • NEERA - Woburn - Woburn

California

  • Global Research Management - Glendale
  • Nvision - La Mesa - La Mesa
  • Nvision - Torrance - Torrance

Tennessee

  • Advancing Vision Research - Goodlettsville
  • Total Eye Care, PA - Memphis
  • Advancing Vision Research - Smyrna

North Carolina

  • Oculus Research - Garner
  • Wilmington Eye - Leland

Arizona

  • Cornea and Cataract Consultants of Arizona - Phoenix

Illinois

  • Wyse Eyecare - Northbrook

Indiana

  • Pankratz Eye - Columbus

Kentucky

  • Butchertown Clinical - Louisville

Trial Details

FieldValue
Enrollment Target 880 participants
Start Date 2024-02-06
Est. Completion 2024-12
Phase Phase 2

Sponsor

Telios Pharma

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06225973

The ClinicalTrials.gov registry entry for NCT06225973 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 880 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 228-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (286% higher). The listed sponsor is Telios Pharma, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dry Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06225973 reports 18 study locations spanning 10 distinct geographic areas - top geographies include Massachusetts, California, Tennessee.

Frequently Asked Questions

What is clinical trial NCT06225973 about?

NCT06225973 is a clinical study titled "A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease". In this prospective, phase 2b, multicenter, randomized, double-masked, vehicle-controlled, parallel-arm study, approximately 880 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive either TL-925 or vehicle as topical ophthalmic eye drops administered bil...

What is the current status of trial NCT06225973?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 880 participants. The study started on 2024-02-06. Estimated completion is 2024-12.

What conditions does trial NCT06225973 study?

This clinical trial studies the following conditions: Dry Eye Disease.

What interventions are being tested in trial NCT06225973?

The interventions under investigation include: Placebo (OTHER), TL-925 (DRUG).

Who is sponsoring clinical trial NCT06225973?

This trial is sponsored by Telios Pharma, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06225973 being conducted?

This trial has 18 study locations across Arizona, California, Illinois, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Dry Eye Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Dry Eye Disease

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.